Use of interferon-α in patients with West Nile encephalitis: Report of 2 cases

Clinical Infectious Diseases

Volumn 40, Issue 5, 2005, Pages 764-766

  Kalil, Andre C ^a   Devetten, Marcel P ^a   Singh, Sanjay ^a   Lesiak, Brandi ^a   Poage, David P ^a   Bargenquast, Kim ^a   Fayad, Pierre ^a   Freifeld, Alison G ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; CEFTRIAXONE; DEXAMETHASONE; HYDROXYCHLOROQUINE; METHOTREXATE;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; EXPERIMENTAL THERAPY; FEMALE; FOLLOW UP; HUMAN; LIVER FUNCTION TEST; MALE; MENINGOENCEPHALITIS; MORTALITY; MYALGIA; NEUROLOGIC EXAMINATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; VIRUS ENCEPHALITIS; WEST NILE FLAVIVIRUS;

ADULT; ANTIVIRAL AGENTS; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; WEST NILE FEVER;

EID: 15044352317     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427945     Document Type: Article

References (22)

1. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358:261-4.
2. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173-9.
3. Anderson JF, Rahal JJ. Efficacy of interferon alpha 2b and ribavirin against West Nile virus in vitro [letter]. Emerg Infect Dis 2002; 8:107-8.
4. Shahar A, Lustig S, Akov Y, David Y, Schneider P, Levin R. Different pathogenicity of encephalitic togaviruses in organotypic cultures of spinal cord slices. J Neurosci Res 1990; 25:345-52.
5. Wang T, Scully E, Yin Z, et al. IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J Immunol 2003; 171:2524-31.
6. Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 2004; 15:101-9.
7. Leyssen P, Drosten C, Paning M, et al. Interferons, Interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother 2003; 47:777-82.
8. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998; 352: 767-71.
9. Brilla R, Block M, Geremia G, Wichter M. Clinical and neuroradiologic features of 39 consecutive cases of West Nile Virus meningoencephalitis. J Neurol Sci 2004; 220:37-40.
10. Weiss D, Carr D, Kellachan J, et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis 2001; 7:654-8.
11. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344: 1807-14.
12. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675-8.
13. Pepperell C, Rau N, Krajden S, et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ 2003; 168:1399-405.
14. New York City Department of Health and Mental Hygiene. West Nile virus surveillance and control: an update for healthcare providers in New York City. City Health Information 2001.
15. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290:511-5.
16. Ravindra KV, Freifeld AG, Kalil AC, et al. West Nile virus-associated encephalitis in recipients of renal and pancreas transplants: case series and literature review. Clin Infect Dis 2004; 38:1257-60.
17. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9:376-9.
18. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46:563-70.
19. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985; 37:85-8.
20. Rahal JJ, Anderson J, Rosenberg C, Reagan T, Thompson LL. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 2004; 190: 1084-7.
21. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-100.
22. Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003; 361:821-6.